Post-operative Nausea and Vomiting (PONV) Market (Treatment Type - Serotonin Antagonists, Steroids, Dopamine Antagonists, NK-1 Receptor Antagonists, Non-pharmacological Treatment; Distribution Channel - Hospital Pharmacies, Online Pharmacies, Retail Pharmacies & Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2030

Description

Post-operative Nausea and Vomiting (PONV) Market - Snapshot

The global post-operative nausea and vomiting (PONV) market is growing at a significant rate due to bourgeoning incidence rate of post-operative complications and increasing demand for combination therapy, as well as introduction of promising drugs in this segment across the globe. The global PONV market was valued at US$ 1,608.6 Mn in 2017. It is projected to register a compound annual growth rate (CAGR) of 8.1% from 2018 to 2026 to reach a value of the US$ 3,174.1 Mn by 2026. The market is witnessing a relatively moderate growth owing to increase in patient population experiencing post-operative nausea and vomiting and rise in the rate of adoption of combination therapies as well as non-pharmacological treatment modes globally.

According to treatment guidelines, the suggested pharmacologic anti-emetics for prophylaxis  of PONV in adults include serotonin antagonists; such as, ramosetron, granisetron, palonosetron, ondansetron, dolasetron, and tropisetron, neurokinin-1 (NK-1) receptor antagonists; such as aprepitant, and rolapitant, steroids; such as dexamethasone and methylprednisolone, dopamine antagonists as transdermal scopolamine [TDS] and others; such as butyrophenones as well as antihistamines (dimenhydrinate and meclizine). Postoperative nausea and vomiting is considered a major clinical issue that can diminish a patient’s quality of life. Additionally, PONV leads to an increase in perioperative costs as well as morbidity, lengthens stay at the post-anesthesia care unit, increases hospital stay, delays the time taken by the patient to go back to work, and results in readmissions. Irrespective of the availability of multiple tools to segment patients as per PONV development risk criteria and treatment guidelines, physicians are unable to methodically address prophylaxis or treatment of PONV in a uniform manner through pharmacologic or non-pharmacologic strategies.

Major factors boosting the growth of the post-operative nausea and vomiting market include large number of surgeries performed and rise in the rate of postoperative complications, such as, dizziness, vomiting, and nausea. However, strict regulatory approvals and high health care expenditure are predicted to hamper the growth of the PONV market during the forecast period.

The global post-operative nausea and vomiting (PONV) market has been divided into three segments based on treatment type, distribution pattern, and geography. In terms of treatment type, the PONV market has been segmented into serotonin antagonists, steroids, dopamine antagonists, NK-1 receptor antagonists, others, and non-pharmacological treatment. Serotonin antagonist is expected to command the dominant share of the market owing to its proven safety profile and effectiveness, as well as for being physicians’ first preference drug in the management of post-operative nausea and vomiting. The non-pharmacologic treatment segment is expected to expand at a CAGR of 7.6% by 2026, owing to cost-effectiveness of the methods, such as, acupuncture, acupressure, and electrical acustimulation in the treatment of post-operative nausea and vomiting.

In terms of distribution pattern, the global post-operative nausea and vomiting (PONV) market has been classified into hospital pharmacies, online pharmacies, and retail pharmacies and online stores. The hospital pharmacies segment constitutes a major share of the PONV market owing to rising investment in the hospital sector, particularly in emerging countries, which is boosting the number of hospitals in these countries. This, in turn, is anticipated to increase the number of hospital pharmacies, thus improving accessibility to medications used in the treatment of PONV.

Geographically, the post-operative nausea and vomiting (PONV) market has been categorized into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the leading share of the global PONV market in 2017, followed by Europe, with a substantial market share. Presence of a large base of surgical patients as well as readiness among patients to pay extra money in order to avoid post-operative complications are expected to propel the PONV market in North America during the forecast period. Europe commands the second leading share of the global post-operative nausea and vomiting (PONV) market. High incidence rate of PONV among surgical patients in Europe and rise in R&D expenditure in pharmaceuticals are projected to lead to a large market size of the region.

Leading players operating in the global post-operative nausea and vomiting (PONV) market include Acacia Pharma, F. Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc., Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, Merck and Co., and GlaxoSmithKline Corporation.

The global PONV market has been segmented as follows:

Treatment

  • Serotonin Antagonists
  • Steroids
  • Dopamine Antagonists
  • NK-1 Receptor Antagonists
  • Others
  • Non-pharmacologic Treatment

Application

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies and Drug Stores

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC
  • South Africa
  • Israel
  • Rest of Middle East & Africa

TABLE OF CONTENT

Chapter 1 Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2 Assumptions and Research Methodology

Chapter 3 Executive Summary: Global Post-operative Nausea and Vomiting (PONV) Market

Chapter 4 Market Overview
4.1. Introduction
4.2. Key Industry Developments

Chapter 5 Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Trends
5.5. Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, 2016–2026
5.6. Global Post-operative Nausea and Vomiting (PONV) Market Outlook

Chapter 6 Market Outlook
6.1. Absolute Surgical Procedure Volume, by Region
6.2. Incidence of Post-operative Nausea and Vomiting, by Region, (2017 - Estimated)
6.3. Post-operative Nausea and Vomiting (PONV) Market: Pipeline Analysis

Chapter 7 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Treatment Type
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
       7.3.1. Serotonin Antagonists
       7.3.2. Steroids
       7.3.3. Dopamine Antagonists
       7.3.4. NK-1 receptor Antagonists
       7.3.5. Non-Pharmacologic Treatment
7.4. Market Attractiveness Analysis, by Treatment Type

Chapter 8 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Distribution Channel
8.1. Key Findings
8.2. Global PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
       8.2.1. Hospital Pharmacies
       8.2.2. Online Pharmacies
       8.2.3. Retail Pharmacies and Drug Stores
8.3. Global PONV Market Attractiveness Analysis, by Distribution Channel
8.4. Key Trends

Chapter 9 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Global PONV Market Value (US$ Mn) Forecast, by Region, 2018–2026
       9.3.1. North America
       9.3.2. Europe
       9.3.3. Asia Pacific
       9.3.4. Latin America
       9.3.5. Middle East & Africa
9.4. Global PONV Market Attractiveness Analysis, by Region

Chapter 10 North America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
10.1. Key Findings
10.2. North America PONV Market Size (US$ Mn) Forecast, by Country, 2018–2026
       10.2.1. U.S.
       10.2.2. Canada
10.3. North America PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
       10.3.1. Serotonin Antagonists
       10.3.2. Steroids
       10.3.3. Dopamine Antagonists
       10.3.4. NK-1 receptor Antagonists
       10.3.5. Non-pharmacologic Treatment
10.4. North America PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
       10.4.1. Hospital Pharmacies
       10.4.2. Online Pharmacies
       10.4.3. Retail Pharmacies and Drug Stores
10.5. North America PONV Market Attractiveness Analysis
       10.5.1. By Country
       10.5.2. By Treatment Type
       10.5.3. By Distribution Channel

Chapter 11 Europe Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
11.1. Key Findings
11.2. Europe PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
       11.2.1. Germany
       11.2.2. U.K.
       11.2.3. France
       11.2.4. Italy
       11.2.5. Spain
       11.2.6. Russia
       11.2.7. Rest of Europe
11.3. Europe PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
       11.3.1. Serotonin Antagonists
       11.3.2. Steroids
       11.3.3. Dopamine Antagonists
       11.3.4. NK-1 receptor Antagonists
       11.3.5. Non-Pharmacologic Treatment
11.4. Europe PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
       11.4.1. Hospital Pharmacies
       11.4.2. Online Pharmacies
       11.4.3. Retail Pharmacies and Drug Stores
11.5. Europe PONV Market Attractiveness Analysis
       11.5.1. By Country
       11.5.2. By Treatment Type
       11.5.3. By Distribution Channel

Chapter 12 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
       12.3.1. China
       12.3.2. India
       12.3.3. Japan
       12.3.4. Australia & New Zealand
       12.3.5. Rest of Asia Pacific
12.4. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
       12.4.1. Serotonin Antagonists
       12.4.2. Steroids
       12.4.3. Dopamine Antagonists
       12.4.4. NK-1 receptor Antagonists
       12.4.5. Non-Pharmacologic Treatment
12.5. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
       12.5.1. Hospital Pharmacies
       12.5.2. Online Pharmacies
       12.5.3. Retail Pharmacies and Drug Stores
12.6. Asia Pacific PONV Market Attractiveness Analysis
       12.6.1. By Country
       12.6.2. By Treatment Type
       12.6.3. By Distribution Channel

Chapter 13 Latin America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Latin America PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
       13.3.1. Brazil
       13.3.2. Mexico
       13.3.3. Rest of Latin America
13.4. Latin America PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
       13.4.1. Serotonin Antagonists
       13.4.2. Steroids
       13.4.3. Dopamine Antagonists
       13.4.4. NK-1 receptor Antagonists
       13.4.5. Non-Pharmacologic Treatment
13.5. Latin America PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
       13.5.1. Hospital Pharmacies
       13.5.2. Online Pharmacies
       13.5.3. Retail Pharmacies and Drug Stores
13.6. Latin America PONV Market Attractiveness Analysis
       13.6.1. By Country
       13.6.2. By Treatment Type
       13.6.3. By Distribution Channel

Chapter 14 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
       14.3.1. GCC Countries
       14.3.2. South Africa
       14.3.3. Israel
       14.3.4. Rest of Middle East & Africa
14.4. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
       14.4.1. Serotonin Antagonists
       14.4.2. Steroids
       14.4.3. Dopamine Antagonists
       14.4.4. NK-1 receptor Antagonists
       14.4.5. Non-Pharmacologic Treatment
14.5. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
       14.5.1. Hospital Pharmacies
       14.5.2. Online Pharmacies
       14.5.3. Retail Pharmacies and Drug Stores
14.6. Middle East & Africa PONV Market Attractiveness Analysis
       14.6.1. By Country
       14.6.2. By Treatment Type
       14.6.3. By Distribution Channel

Chapter 15 Competition Landscape
15.1. Global Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Key Players and Their Competitive Positioning
15.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
       15.3.1. Acacia Pharma
                 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.1.2. Product Portfolio
                 15.3.1.3. SWOT Analysis
                 15.3.1.4. Strategic Overview
       15.3.2. F. Hoffmann La Roche Ltd.
                 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.2.2. Product Portfolio
                 15.3.2.3. SWOT Analysis
                 15.3.2.4. Strategic Overview
       15.3.3. ANI Pharmaceuticals
                 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.3.2. Product Portfolio
                 15.3.3.3. SWOT Analysis
                 15.3.3.4. Financial Overview
                 15.3.3.5. Strategic Overview
       15.3.4. Sanofi
                 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.4.2. Product Portfolio
                 15.3.4.3. SWOT Analysis
                 15.3.4.4. Financial Overview
                 15.3.4.5. Strategic Overview
       15.3.5. GlaxoSmithKline Corporation
                 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.5.2. Product Portfolio
                 15.3.5.3. SWOT Analysis
                 15.3.5.4. Financial Overview
                 15.3.5.5. Strategic Overview
       15.3.6. Eisai Co., Inc.
                 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.6.2. Product Portfolio
                 15.3.6.3. SWOT Analysis
                 15.3.6.4. Financial Overview
                 15.3.6.5. Strategic Overview
       15.3.7. Merck KGaA
                 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.7.2. Product Portfolio
                 15.3.7.3. SWOT Analysis
                 15.3.7.4. Financial Overview
                 15.3.7.5. Strategic Overview
       15.3.8. Novartis AG
                 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.8.2. Product Portfolio
                 15.3.8.3. SWOT Analysis
                 15.3.8.4. Financial Overview
                 15.3.8.5. Strategic Overview
       15.3.9. Helsinn Holding Co.
                 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.9.2. Product Portfolio
                 15.3.9.3. SWOT Analysis
                 15.3.9.4. Financial Overview
                 15.3.9.5. Strategic Overview
       15.3.10. Camurus AB
                 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.10.2. Product Portfolio
                 15.3.10.3. SWOT Analysis
                 15.3.10.4. Financial Overview
                 15.3.10.5. Strategic Overview

Choose License Type

Checkout Inquiry Sample